Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM. Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer 60: 14-21, 2008.Revue systématique

Hashizume T, Yamada K, Okamoto N, Saito H, Oshita F, Kato Y, et al. Prognostic significance of thin-section CT scan findings in small-sized lung adenocarcinoma. Chest 2008 Feb;133(2):441-7.Etude rétrospective

Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proc Am Thorac Soc 2009 Apr 15;6(2):206-17.Revue narrative.

Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009 Aug 5;101(15):1049-57. Etude de phase III randomisée (commerciale)

Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Jr., Onn A. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 3: 351-7, 2008.Etude rétrospective.

Reck M, von PJ, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009 Mar 10;27(8):1227-34. Etude de phase III (commerciale)

Gabrijel S, Grize L, Helfenstein E, Brutsche M, Grossman P, Tamm M, et al. Receiving the diagnosis of lung cancer: patient recall of information and satisfaction with physician communication. J Clin Oncol 2008 Jan 10;26(2):297-302.Enquête.

Park HY, Kim YH, Kim H, Koh WJ, Suh GY, Chung MP, et al. Routine screening by brain magnetic resonance imaging decreased the brain metastasis rate following surgery for lung adenocarcinoma. Lung Cancer 2007 Oct;58(1):68-72.Etude rétrospective.

Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer 112: 1827-34, 2008.Etude rétrospective.

Song JW, Oh YM, Shim TS, Kim WS, Ryu JS, Choi CM. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer. Lung Cancer 2009 Sep;65(3):333-8. Etude rétrospective.

Yasufuku K, Nakajima T, Chiyo M, Sekine Y, Shibuya K, Fujisawa T. Endobronchial ultrasonography: current status and future directions. J Thorac Oncol 2007 Oct;2(10):970-9.Revue narrative.

Barillot E, Calzone L, Zinovyev A. Biologie des systèmes appliqués aux cancers. Med Sci (Paris) 2009 Jun;25(6-7):601-7. Revue narrative.

Borczuk AC, Toonkel RL, Powell CA. Genomics of lung cancer. Proc Am Thorac Soc 2009 Apr 15;6(2):152-8.Revue narrative.

Chao YC, Pan SH, Yang SC et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 2009 January 15;179(2):123-33.Etude rétrospective.

Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med 2008 Dec 25;359(26):2814-23.Revue narrative.

Esteller M. Epigenetics in cancer. N Engl J Med 2008 Mar 13;358(11):1148-59.Revue narrative.

Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small-cell lung cancer. Ann Oncol 19: 1219-23, 2008. revue narrative.

Lee DH, Kim SK, Lee HY, Lee SY, Park SH, Kim HY, et al. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol 2009 Jul;4(7):816-21.Etude rétrospective.

Lo KC, Stein LC, Panzarella JA, Cowell JK, Hawthorn L. Identification of genes involved in squamous cell carcinoma of the lung using synchronized data from DNA copy number and transcript expression profiling analysis. Lung Cancer 59: 315-31, 2008.Analyse du transcriptome.

Ocak S, Sos ML, Thomas RK, Massion PP. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J 2009 Aug;34(2):489-506. Revue narrative.

Weiss GJ, Kingsley C. Pathway targets to explore in the treatment of non-small cell lung cancer. J Thorac Oncol 2008 Nov;3(11):1342-52.Revue narrative.

Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009 Apr 15;115(8):1723-33. Etude rétrospective.

Lee BE, Port JL, Stiles BM, Saunders J, Paul S, Lee PC, et al. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg 2009 Oct;88(4):1100-5. Etude rétrospective.

Riquet M, Cazes A, Pfeuty K, Ngabou UD, Foucault C, Dujon A, et al. Multiple lung cancers prognosis: what about histology? Ann Thorac Surg 2008 Sep;86(3):921-6.Etude rétrospective.

Bergot E, Levallet G, Zalcman G. Susceptibilité génétique au cancer bronchique et à l'addiction tabagique : vers une explication moléculaire ? Rev Mal Respir 25: 519-22, 2008.Editorial.

Dacic S. Pulmonary preneoplasia. Arch Pathol Lab Med 2008 Jul;132(7):1073-8.Revue narrative.

Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martinez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcatova I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-7, 2008.Etude cas-témoin.

Kased N, Erasmus JJ, Komaki R, Cox JD. Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review. J Thorac Oncol 3: 534-8, 2008.Etude rétrospective.

Klein F, min Kotb WF, Petersen I. Incidence of human papilloma virus in lung cancer. Lung Cancer 2009 Jul;65(1):13-8. Revue systématique.

Li Y, Qiu LX, Shen XK, Lv XJ, Qian XP, Song Y. A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer 2009 Oct;66(1):15-21. Méta-analyse

McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008 Dec;40(12):1404-6.Etude prospective.

Massion PP, Zou Y, Chen H, Jiang A, Coulson P, Amos CI, et al. Smoking-related genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med 2008 Dec 1;178(11):1164-72.Etude rétrospective.

Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 26: 2883-9, 2008.Revue narrative.

Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010 Jan 14;463(7278):184-90. Etude de laboratoire sur lignée.

Salaun M, Sesboue R, Moreno-Swirc S, Metayer J, Bota S, Bourguignon J, Thiberville L. Molecular predictive factors for progression of high-grade preinvasive bronchial lesions. Am J Respir Crit Care Med 177: 880-6, 2008.Etude prospective.

Sin DD, Man SF, McWilliams A, Lam S. Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer. Chest 2008 Sep;134(3):582-8.Etude rétrospective.

Soh J, Toyooka S, Ichihara S, Asano H, Kobayashi N, Suehisa H, Otani H, Yamamoto H, Ichimura K, Kiura K, Gazdar AF, Date H. Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. J Thorac Oncol 3: 340-7, 2008. Etude rétrospective.

Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsater A, Flex A, Aben KK, de VF, Mulders PF, Isla D, Vidal MJ, Asin L, Saez B, Murillo L, Blondal T, Kolbeinsson H, Stefansson JG, Hansdottir I, Runarsdottir V, Pola R, Lindblad B, van Rij AM, Dieplinger B, Haltmayer M, Mayordomo JI, Kiemeney LA, Matthiasson SE, Oskarsson H, Tyrfingsson T, Gudbjartsson DF, Gulcher JR, Jonsson S, Thorsteinsdottir U, Kong A, Stefansson K. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-42, 2008.Etude cas-témoin.

Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA, et al. MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol 2009 Aug;4(8):1028-34. Revue narrative.

Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68: 2106-11, 2008.Etude rétrospective.

Moro-Sibilot D, Lantuejoul S, Diab S, Moulai N, Aubert A, Timsit JF, Brambilla C, Brichon PY, Brambilla E. Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis. Eur Respir J 31: 854-9, 2008.Etude rétrospective.

Keith RL. Chemoprevention of lung cancer. Proc Am Thorac Soc 2009 Apr 15;6(2):187-93.Revue narrative.

Tan XL, Spivack SD. Dietary chemoprevention strategies for induction of phase II xenobiotic-metabolizing enzymes in lung carcinogenesis: A review. Lung Cancer 2009 Aug;65(2):129-37.Revue narrative.

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008 Oct 1;26(28):4617-25.Méta-analyse.

Azim HA, Jr., Elattar I, Loberiza FR, Jr. et al. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer 2009; 64(2):194-8. Revue systématique.

Berghmans T, Lafitte JJ, Lecomte J, Alexopoulos CG, Van CO, Giner V, Efremidis A, Berchier MC, Collon T, Meert AP, Scherpereel A, Ninane V, Leclercq N, Paesmans M, Sculier JP. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. Br J Cancer 96: 1644-9, 2007. Etude randomisée de phase III.

Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009 Oct 24;374(9699):1432-40.Etude randomisée de phase III (commerciale).

Cullen MH, Zatloukal P, Sorenson S, Novello S, Fischer JR, Joy AA, Zereu M, Peterson P, Visseren-Grul CM, Iscoe N. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19: 939-45, 2008.Etude de phase III (commerciale).

Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007 Oct;2(10):939-46.Méta-analyse de la littérature.

Fidias PM, Dakhil SR, Lyss AP et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009 February 1;27(4):591-8.Etude de phase III (commerciale).

Gao G, Jiang J, Liang X, Zhou X, Huang R, Chu Z, et al. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009 Sep;65(3):339-44. Méta-analyse de la littérature.

Gebbia V, Gridelli C, Verusio C et al. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial. Lung Cancer 2009 February;63(2):251-8.Etude de phase II randomisée (académique)

Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer 2008 Jan;59(1):57-63; Etude de phase III.

Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010 Feb;5(2):260-74. Revue systématique.

Goto Y, Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients. J Thorac Oncol 3: 412-6, 2008.Etude rétrospective.

Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009 Jul 1;27(19):3217-24. Etude de phase III (commerciale)

Hainsworth JD, Spigel DR, Farley C, Shipley DL, Bearden JD, Gandhi J, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007 Nov 1;110(9):2027-34 Etude randomisée de phase III.

Helbekkmo N, Sundstrom SH, Aasebo U, Brunsvig PF, von PC, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97: 283-9, 2007.Etude de phase III randomisée.

Helbekkmo N, Aasebo U, Sundstrom SH, von PC, Brunsvig PF, Bremnes RM. Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer 2008 Nov;62(2):253-60. Etude rétrospective.

Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, et al. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. Am J Clin Oncol 2007 Jun;30(3):245-51.Etude de phase II randomisée.

Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57: 348-58, 2007.Méta-analyse de la littérature.

Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM, Jr., Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer 60: 200-7, 2008.Etude de phase III randomisée (académique).

Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3: 623-30, 2008.Etude de phase III (commerciale)

Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 2009 Mar;45(4):601-7. Revue systématique.

Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 Aug 20;26(24):3979-86.Etude de phase III (commerciale)

O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3: 728-34, 2008.Etude de phase III (commerciale)

Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, von PJ, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 2008 May 20;98(10):1608-13.Etude de phase III (commerciale)

Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008 Jan;59(1):1-11.Revue systématique.

Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009 Dec 1;27(34):5808-15. Etude de phase III (commerciale)

Scagliotti GV, Parikh P, von PJ, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 Jul 20;26(21):3543-51.Etude de phase III (commerciale)

Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009 Jul 10;27(20):3277-83. Revue systématique.

Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010 Feb 10;28(5):753-60. Etude de phase III

Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P, et al. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 2009 Jun;135(6):1596-609. revue systématique.

Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. Br J Cancer 2009 February 10;100(3):436-41.Revue systématique avec méta-analyse (académique)

Wibmer T, Kropf C, Merk T, Schumann C, Hombach V, Kruger S. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer. Lung Cancer 60: 231-9, 2008.Etude de phase II (académique).

Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010 Feb 1;28(4):620-7.Etude de registre.

Gridelli C, Maione P, Illiano A, Piantedosi FV, Favaretto A, Bearz A, Robbiati SF, Filipazzi V, Lorusso V, Carrozza F, Iaffaioli RV, Manzione L, Gallo C, Morabito A, Perrone F. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol 25: 4663-9, 2007.Analyse rétrospective.

Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, et al. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 2009 May 1;115(9):1924-31. Revue systématique.

Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, Lee JS. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer. Cancer 113: 388-95, 2008. Etude de pase II randomisée (académique)

Jones S, Thompson D, Barton J, Patton J, Shipley D, Greco FA, Spigel D, Infante J, Burris HA, III. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clin Lung Cancer 9: 154-9, 2008.Etude de pase II randomisée (commerciale)

Albain KS, Swann RS, Rusch VW, Turrisi AT, III, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009 Aug 1;374(9687):379-86.Etude randomisée (académique)

Anraku M, Waddell TK, de PM, Lewis SJ, Pierre AF, Darling GE, et al. Induction chemoradiotherapy facilitates radical resection of T4 non-small cell lung cancer invading the spine. J Thorac Cardiovasc Surg 2009 Feb;137(2):441-7.Etude rétrospective.

Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010 Jan 1;28(1):35-42. Etude randomisée (académique)

Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol 2008 Nov 1;26(31):5052-9.etude randomisée.

Bria E, Gralla RJ, Raftopoulos H et al. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2009 January;63(1):50-7.Méta-analyse.

Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010 Jan 1;28(1):29-34. (étude randomisée)

Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, et al. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer. J Thorac Oncol 2008 Jan;3(1):37-45.Petites études randomisées.

Fruh M, Rolland E, Pignon JP, Seymour L, Ding K, Tribodet H, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol 2008 Jul 20;26(21):3573-81.Etude "poolée".

Garrido P, Gonzalez-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 25: 4736-42, 2007.Etude de phase II.

Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, Smit H, van MJ, Nankivell M, Parmar M, Pugh C, Stephens R. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 369: 1929-37, 2007.Etude randomisée de phase III.

Hamada C, Tsuboi M, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol 2009 Dec;4(12):1511-6. Méta-analyse.

Jang RW, Le MA, Ding K, Winton T, Bezjak A, Seymour L, et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol 2009 Sep 10;27(26):4268-73. Etude académique (?)

Lang K, Marciniak MD, Faries D et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009 February;63(2):264-70. Etude de registre.

Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2009 Nov;4(11):1380-8.Revue systématique.

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008 Jul 20;26(21):3552-9.Etude "poolée".

Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn JR, Ung YC, Shepherd FA. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline. J Clin Oncol 25: 5506-18, 2007.Recommandations de pratique clinique.

Pisters KM, Vallieres E, Crowley JJ, Franklin WA, Bunn PA, Jr., Ginsberg RJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 2010 Apr 10;28(11):1843-9.Etude académique randomisée de phase III.

Steger V, Walles T, Kosan B, Walker T, Kyriss T, Veit S, et al. Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival. Ann Thorac Surg 2009 Jun;87(6):1676-83. Etude rétrospective.

Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008 Nov 1;26(31):5043-51.Etude de phase III.

Thomas M, Rube C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008 Jul;9(7):636-48. Etude de phase III (académique)

Felip E, Rosell R, Maestre JA, Rodriguez-Paniagua JM, Moran T, Astudillo J, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010 Jul 1;28(19):3138-45. Etude de phase III (académique)

Baka S, Califano R, Ferraldeschi R, Aschroft L, Thatcher N, Taylor P, Faivre-Finn C, Blackhall F, Lorigan P. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Br J Cancer 99: 442-7, 2008.Etude de phase III (académique).

de Jong WK, Groen HJ, Koolen MG, Biesma B, Willems LN, Kwa HB, et al. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer. Eur J Cancer 2007 Nov;43(16):2345-50.Etude de phase III.

Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008 Sep 10;26(26):4261-7Etude de phase III randomisée (commerciale).

Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 2008;26:5401-5406.Etude de phase II randomisée (académique).

Jiang J, Shi HZ, Deng JM, Liang QL, Qin SM, Wu C. Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature. Lung Cancer 2009 Aug;65(2):214-8. Méta-analyse

Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H, Kubota K, et al. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer 2008 Nov 1;113(9):2518-23.Etude rétrospective.

Lara PN, Jr., Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009 May 20;27(15):2530-5.Etude de phase III randomisée (académique).

Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, Peters S, Brunsvig P, Montes A, Lange A, Yilmaz U, Rosti G. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 100: 533-41, 2008.Etude randomisée (académique).

Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T, Saijo N. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97: 162-9, 2007.Etude de phase III.

Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Geneve J, Maraninchi D. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 25: 3945-51, 2007.Etude de phase III.

Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009 Oct 1;27(28):4787-92. Etude de phase III. (commerciale)

Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010 Jun;5(6):867-73. Méta-analyse.

Pennathur A, Lindeman B, Ferson P, Ninan M, Quershi I, Gooding WE, et al. Surgical resection is justified in non-small cell lung cancer patients with node negative T4 satellite lesions. Ann Thorac Surg 2009 Mar;87(3):893-9. Etude rétrospective.

Thomas P, Dahan M, Riquet M, Massart G, Falcoz PE, Brouchet L, et al. Pratiques chirurgicales dans le traitement du cancer primitif non à petites cellules du poumon. Recommandations de la SFCTCV : pratiques chirurgicales dans le traitement du cancer du poumon. Rev Mal Respir 2008 Oct;25(8):1031-6. Recommandations de pratique clinique.

Vlastos F, Lacomme S, Wild P, Poulain S, Siat J, Grosdidier G, et al. Do evolving practices improve survival in operated lung cancer patients? A biobank may answer. J Thorac Oncol 2009 Apr;4(4):505-11.Etude rétrospective.

Obuchi T, Hamanaka W, Yoshida Y, Yanagisawa J, Hamatake D, Shiraishi T, et al. Clinical outcome after pulmonary resection for lung cancer patients on hemodialysis. Ann Thorac Surg 2009 Dec;88(6):1745-8. Série de cas.

Alam N, Park BJ, Wilton A, Seshan VE, Bains MS, Downey RJ, et al. Incidence and risk factors for lung injury after lung cancer resection. Ann Thorac Surg 2007 Oct;84(4):1085-91.Etude cas-témoin rétrospective.

Berry MF, Villamizar-Ortiz NR, Tong BC, Burfeind WR, Jr., Harpole DH, D'Amico TA, et al. Pulmonary function tests do not predict pulmonary complications after thoracoscopic lobectomy. Ann Thorac Surg 2010 Apr;89(4):1044-51.Etude rétrospective.

Bryant AS, Cerfolio RJ. The analysis of a prospective surgical database improves postoperative fast-tracking algorithms after pulmonary resection. J Thorac Cardiovasc Surg 2009 May;137(5):1173-9. Etude rétrospective.

Li WW, Visser O, Ubbink DT, Klomp HM, Kloek JJ, de Mol BA. The influence of provider characteristics on resection rates and survival in patients with localized non-small cell lung cancer. Lung Cancer 60: 441-51, 2008.etude de registre.

Mason DP, Subramanian S, Nowicki ER, Grab JD, Murthy SC, Rice TW, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. Ann Thorac Surg 2009 Aug;88(2):362-70. Etude rétrospective.

Ost D, Goldberg J, Rolnitzky L, Rom WN. Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med 177: 516-23, 2008; Etude rétrospective.

Radu DM, Jaureguy F, Seguin A, Foulon C, Destable MD, Azorin J, et al. Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery. Ann Thorac Surg 2007 Nov;84(5):1669-73.Etude rétrospective.

Sioris T, Sihvo E, Sankila R, Salo J. Effect of surgical volume and hospital type on outcome in non-small cell lung cancer surgery: a Finnish population-based study. Lung Cancer 2008 Jan;59(1):119-25.Etude rétrospective.

Strand TE, Rostad H, Damhuis RA, Norstein J. Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude. Thorax 2007 Nov;62(11):991-7.Etude de registre.

Subotic DR, Mandaric DV, Eminovic TM, Gajic MM, Mujovic NM, Atanasijadis ND, et al. Influence of chronic obstructive pulmonary disease on postoperative lung function and complications in patients undergoing operations for primary non-small cell lung cancer. J Thorac Cardiovasc Surg 2007 Nov;134(5):1292-9.Etude rétrospective.

Wright CD, Gaissert HA, Grab JD, O'Brien SM, Peterson ED, Allen MS. Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. Ann Thorac Surg 85: 1857-65, 2008.Etude de cohorte.

Brunelli A, Refai M, Xiume F, Salati M, Sciarra V, Socci L, Sabbatini A. Performance at symptom-limited stair-climbing test is associated with increased cardiopulmonary complications, mortality, and costs after major lung resection. Ann Thorac Surg 86: 240-7, 2008. Etude rétrospective.

Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J 2009 Jul;34(1):17-41. Recommandations de pratique clinique.

Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg 2009 Jul;36(1):181-4. Recommandations de pratique clinique

Charloux A, Brunelli A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al. Lung function evaluation before surgery in lung cancer patients: how are recent advances put into practice? A survey among members of the European Society of Thoracic Surgeons (ESTS) and of the Thoracic Oncology Section of the European Respiratory Society (ERS). Interact Cardiovasc Thorac Surg 2009 Dec;9(6):925-31. Enquête.

Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, et al. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest 2009 Jun;135(6):1588-95. Analyse rétrolective.

van Tilburg PM, Stam H, Hoogsteden HC, van Klaveren RJ. Pre-operative pulmonary evaluation of lung cancer patients: a review of the literature. Eur Respir J 2009 May;33(5):1206-15.Revue narrative.

Cassivi SD, Allen MS, Vanderwaerdt GD, Ewoldt LL, Cordes ME, Wigle DA, et al. Patient-centered quality indicators for pulmonary resection. Ann Thorac Surg 2008 Sep;86(3):927-32.Etude rétrospective.

Farjah F, Flum DR, Varghese TK, Jr., Symons RG, Wood DE. Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg 2009 Apr;87(4):995-1004.Etude rétrospective.

Boffa DJ, Allen MS, Grab JD, Gaissert HA, Harpole DH, Wright CD. Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg 2008 Feb;135(2):247-54.Etude de banque de données prospectives.

Collaud S, Bongiovanni M, Pache JC, Fioretta G, Robert JH. Survival according to the site of bronchial microscopic residual disease after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg 2009 Mar;137(3):622-6.Etude rétrospective.

Esnaola NF, Gebregziabher M, Knott K, Finney C, Silvestri GA, Reed CE, Ford ME. Underuse of surgical resection for localized, non-small cell lung cancer among whites and African Americans in South Carolina. Ann Thorac Surg 86: 220-6, 2008.Etude de registre.

Farjah F, Wood DE, Yanez D, III, Symons RG, Krishnadasan B, Flum DR. Temporal trends in the management of potentially resectable lung cancer. Ann Thorac Surg 85: 1850-5, 2008.Etude de registre.

Farjah F, Wood DE, Varghese TK, Jr., Symons RG, Flum DR. Trends in the operative management and outcomes of T4 lung cancer. Ann Thorac Surg 2008 Aug;86(2):368-74.Etude de registre.

Hung JJ, Hsu WH, Hsieh CC et al. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax 2009 March;64(3):192-6. Etude rétrospective.

Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D'Amico TA, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 2009 Nov 15;115(22):5218-27. Etude rétrospective.

Koike T, Yamato Y, Asamura H, Tsuchiya R, Sohara Y, Eguchi K, et al. Improvements in surgical results for lung cancer from 1989 to 1999 in Japan. J Thorac Oncol 2009 Nov;4(11):1364-9.Etude rétrospective.

Riquet M, Achour K, Foucault C, Le Pimpec BF, Dujon A, Cazes A. Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis. Ann Thorac Surg 2010 Mar;89(3):870-5. Résultats.

Varlotto JM, Flickinger JC, Recht A, Nikolov MC, DeCamp MM. A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy. Cancer 112: 1547-54, 2008.Etude de registre (SEER).

Varlotto JM, Recht A, Flickinger JC et al. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer 2009 March 1;115(5):1059-69.Etude rétrospective.

Yildizeli B, Dartevelle PG, Fadel E, Mussot S, Chapelier A. Results of primary surgery with T4 non-small cell lung cancer during a 25-year period in a single center: the benefit is worth the risk. Ann Thorac Surg 2008 Oct;86(4):1065-75.Etude rétrospective.

Berry MF, Hanna J, Tong BC, Burfeind WR, Jr., Harpole DH, D'Amico TA, et al. Risk factors for morbidity after lobectomy for lung cancer in elderly patients. Ann Thorac Surg 2009 Oct;88(4):1093-9. Etude rétrospective.

Kilic A, Schuchert MJ, Pettiford BL et al. Anatomic segmentectomy for stage I non-small cell lung cancer in the elderly. Ann Thorac Surg 2009; 87(6):1662-6. Etude rétrospective.

Mun M, Kohno T. Video-assisted thoracic surgery for clinical stage I lung cancer in octogenarians. Ann Thorac Surg 2008 Feb;85(2):406-11. Etude rétrospective.

Okami J, Higashiyama M, Asamura H, Goya T, Koshiishi Y, Sohara Y, et al. Pulmonary Resection in Patients Aged 80 Years or Over with Clinical Stage I Non-small Cell Lung Cancer: Prognostic Factors for Overall Survival and Risk Factors for Postoperative Complications. J Thorac Oncol 2009 Jul 15;4:1247-53. Etude de registre.

Lucchi M, Melfi F, Ribechini A, Dini P, Duranti L, Fontanini G, Mussi A. Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. J Thorac Cardiovasc Surg 134: 373-7, 2007.Etude rétrospective.

Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 2008 Aug;86(2):362-6.Etude rétrospective.

Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008 Sep;86(3):912-20.Etude rétrospective.

Detterbeck F. What to do with "Surprise" N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 2008 Mar;3(3):289-302.Revue narrative.

Mansour Z, Kochetkova EA, Santelmo N, Ducrocq X, Quoix E, Wihlm JM, Massard G. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann Thorac Surg 86: 228-33, 2008. Etude rétrospective.

Ratto GB, Costa R, Maineri P, Alloisio A, Bruzzi P, Dozin B. Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection? J Thorac Cardiovasc Surg 2009 Oct;138(4):849-58. Etude rétrospective.

Suemitsu R, Takeo S, Hamatake M et al. The perioperative complications for elderly patients with lung cancer associated with a pulmonary resection under general anesthesia. J Thorac Oncol 2009 February;4(2):193-7. Etude rétrospective.

Alifano M, Boudaya MS, Salvi M, Collet JY, Dinu C, Camilleri-Broet S, Regnard JF. Pneumonectomy after chemotherapy: morbidity, mortality, and long-term outcome. Ann Thorac Surg 85: 1866-72, 2008.Etude rétrospective.

Allen AM, Mentzer SJ, Yeap BY, Soto R, Baldini EH, Rabin MS, Sugarbaker DJ, Bueno R. Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 112: 1106-13, 2008.Etude rétrospective.

d'Amato TA, Ashrafi AS, Schuchert MJ, Alshehab DS, Seely AJ, Shamji FM, et al. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 2009 Oct;88(4):1079-85.Etude rétrospective.

Gudbjartsson T, Gyllstedt E, Pikwer A, Jonsson P. Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy. Ann Thorac Surg 2008 Aug;86(2):376-82.Etude rétrospective.

Kim DJ, Lee JG, Lee CY, Park IK, Chung KY. Long-term survival following pneumonectomy for non-small cell lung cancer: clinical implications for follow-up care. Chest 2007 Jul;132(1):178-84.Etude rétrospective.

Mansour Z, Kochetkova EA, Santelmo N, Meyer P, Wihlm JM, Quoix E, et al. Risk factors for early mortality and morbidity after pneumonectomy: a reappraisal. Ann Thorac Surg 2009 Dec;88(6):1737-43. Etude rétrospective.

Simon C, Moreno N, Penalver R, Gonzalez G, varez-Fernandez E, Gonzalez-Aragoneses F. The side of pneumonectomy influences long-term survival in stage I and II non-small cell lung cancer. Ann Thorac Surg 2007 Sep;84(3):952-8.Etude rétrospective.

Thibout Y, Guibert B, Bossard N, Tronc F, Tiffet O, de la RE, et al. Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases. J Thorac Oncol 2009 Dec;4(12):1496-503. Etude rétrospective.

Kenny PM, King MT, Viney RC, Boyer MJ, Pollicino CA, McLean JM, et al. Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. J Clin Oncol 2008 Jan 10;26(2):233-41.Etude prospective.

Bando T, Miyahara R, Sakai H et al. A follow-up report on a new method of segmental resection for small-sized early lung cancer. Lung Cancer 2009 January;63(1):58-62. Etude rétrospective.

Koike T, Togashi K, Shirato T, Sato S, Hirahara H, Sugawara M, et al. Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination. Ann Thorac Surg 2009 Oct;88(4):1106-11.Etude prospective.

Nakayama H, Yamada K, Saito H, Oshita F, Ito H, Kameda Y, et al. Sublobar resection for patients with peripheral small adenocarcinomas of the lung: surgical outcome is associated with features on computed tomographic imaging. Ann Thorac Surg 2007 Nov;84(5):1675-9.Etude rétrospective.

Pless M, Gambazzi F, Stillhart P, Lieb T, Brutsche M. Induction chemotherapy followed by parenchyma-sparing surgery in medically inoperable NSCLC-Results of a feasibility study. Lung Cancer 2008 Nov;62(2):228-35.Etude de faisabilité.

Rami-Porta R, Tsuboi M. Sublobar resection for lung cancer. Eur Respir J 2009 February;33(2):426-35.Revue narrative

Schuchert MJ, Pettiford BL, Keeley S, d'Amato TA, Kilic A, Close J, et al. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer. Ann Thorac Surg 2007 Sep;84(3):926-32.Etude rétrospective.

Flores RM, Park BJ, Dycoco J, Aronova A, Hirth Y, Rizk NP, et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg 2009 Jul;138(1):11-8. Etude rétrospective.

Gopaldas RR, Bakaeen FG, Dao TK, Walsh GL, Swisher SG, Chu D. Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13,619 patients. Ann Thorac Surg 2010 May;89(5):1563-70. Etude de registre.

Jones RO, Casali G, Walker WS. Does failed video-assisted lobectomy for lung cancer prejudice immediate and long-term outcomes? Ann Thorac Surg 86: 235-9, 2008.Etude cas-témoins.

Swanson SJ, Herndon JE, D'Amico TA, Demmy TL, McKenna RJ, Jr., Green MR, Sugarbaker DJ. Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. J Clin Oncol 25: 4993-7, 2007. Etude prospective (cohorte).

Yan TD, Black D, Bannon PG, McCaughan BC. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol 2009 May 20;27(15):2553-62.Revue systématique.

Schreiber D, Rineer J, Weedon J, Vongtama D, Wortham A, Kim A, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 2010 Mar 1;116(5):1350-7. Etude de registre.

Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010 Feb;5(2):215-9. Etude de registre.

Tanvetyanon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008 Mar 1;26(7):1142-7.Revue systématique.

Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med 2007 Apr 26;356(17):1742-50.Enquête

Gray SW, Hlubocky FJ, Ratain MJ, Daugherty CK. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol 25: 3488-94, 2007.Enquête.

Irwin RS. The role of conflict of interest in reporting of scientific information. Chest 2009 Jul;136(1):253-9. Revue.

Steinbrook R. Disclosure of industry payments to physicians. N Engl J Med 2008 Aug 7;359(6):559-61. Opinion.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med 357: 2189-94, 2007.Enquête dans les publications.

Weinfurt KP, Hall MA, King NM, Friedman JY, Schulman KA, Sugarman J. Disclosure of financial relationships to participants in clinical research. N Engl J Med 2009 Aug 27;361(9):916-21.

Birchard KR, Hoang JK, Herndon JE, Jr., Patz EF, Jr. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009 February 1;115(3):581-6.Etude rétrospective.

Crabb SJ, Patsios D, Sauerbrei E et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009 January 20;27(3):404-10.Etude rétrospective.

Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009 Mar;4(3):311-7.Analyse de littérature.

Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 2009 Sep 2;302(9):977-84.Etude de littérature.

Yamamoto N, Nambu Y, Fujimoto T, Koshiji M. A landmark point analysis with cytotoxic agents for advanced NSCLC. J Thorac Oncol 2009 Jun;4(6):697-701. Etude rétrospective.

Ashraf H, Tonnesen P, Holst PJ, Dirksen A, Thorsen H, Dossing M. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). Thorax 2009 May;64(5):388-92. Etude prospective.

Bertrand D, Righini C, Ferretti G, Brambilla C, Moro-Sibilot D. Diagnostic précoce du cancer bronchique après cancer "tête et cou". Rev Mal Respir 25: 559-68, 2008.Etude prospective.

Claus B, Chalon PX. La réorganisation de l'accès aux ressources scientifiques à destination des institutions fédérales belges de santé : création du VDIC et du portail Vesalius.be. Rev Med Brux 2008 May;29(3):192-6.Article d'intérêt général.

Ferretti G, Félix L, Serra-Tosio G, Brambilla C, Moro-Sibilot D, Brichon PY, et al. Nodules pulmonaires partiellement ou totalement en verre dépoli. Rev Mal Respir 2007;24:1265-76.revue narrative.

Henschke C. Clarification of funding of early lung cancer study. N Engl J Med 358: 1862, 2008.Aveu de conflit d'intérêt.

Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E, Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Alloisio M, Incarbone M, Testori A, Destro A, Cappuzzo F, Roncalli M, Santoro A, Ravasi G. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. Lung Cancer 59: 355-63, 2008.Etude prospective randomisée.

Infante M, Lutman RF, Imparato S et al. Differential diagnosis and management of focal ground-glass opacities. Eur Respir J 2009 April;33(4):821-7.Etude rétrospective.

Jacot W, Lhermitte L, Dossat N, Pujol JL, Molinari N, Daures JP, et al. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes. J Thorac Oncol 2008 Aug;3(8):840-50.Etude de cohorte.

Lefébure P, Blanchon T, Kieffer A, Sarter H, Fournel F, Flahault pour le Groupe Dépiscan. Profil des investigateurs actifs au cours d'un essai clinique en médecine générale. L'expérience Dépiscan, phase pilote d'un essai sur le dépistage du cancer bronchique par le scanner hélicoïdal. Rev Mal Respir 2009 Jan;26(1):45-52.Etude prospective.

McMahon PM, Kong CY, Weinstein MC, Tramontano AC, Cipriano LE, Johnson BE, et al. Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer 2008 Dec 15;113(12):3440-9.Modélisation.

Nojo T, Imanaka Y, Ishizaki T, Sekimoto M, Yoshino M, Kurosawa T, et al. Lung cancer incidence in middle-aged men estimated by low-dose computed tomography screening. Lung Cancer 2009 Jul;65(1):56-61. Etude rétrospective.

Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, et al. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol 2009 May;4(5):608-14. Etude randomisée.

Pelosi G, Sonzogni A, Veronesi G, De CE, Maisonneuve P, Spaggiari L, et al. Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: A baseline and 2-year repeat study. Lung Cancer 2008 Nov;62(2):202-14.Etude prospective.

Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008 Nov 1;26(31):5060-6.Etude cas-témoins.

Roberts HC, Patsios DA, Paul NS, DePerrot M, Teel W, Bayanati H, et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol 2009 May;4(5):620-8. Etude de cohorte.

Schultz EM, Sanders GD, Trotter PR, Patz EF, Jr., Silvestri GA, Owens DK, Gould MK. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax 63: 335-41, 2008. Etude rétrospective.

Sone S, Nakayama T, Honda T, Tsushima K, Li F, Haniuda M, Takahashi Y, Suzuki T, Yamanda T, Kondo R, Hanaoka T, Takayama F, Kubo K, Fushimi H. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. Lung Cancer 58: 329-41, 2007.Etude de cohorte

Tammemagi MC, Freedman MT, Pinsky PF, Oken MM, Hu P, Riley TL, et al. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study. J Thorac Oncol 2009 Jun;4(6):710-21. Etude de cohorte.

Toyoda Y, Nakayama T, Kusunoki Y, Iso H, Suzuki T. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br J Cancer 2008 May 20;98(10):1602-7.Etude prospective.

van den Bergh KA, Essink-Bot ML, Bunge EM, Scholten ET, Prokop M, van Iersel CA, van Klaveren RJ, de Koning HJ. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer 113: 396-404, 2008. Etude randomisée.

Van't Westeinde SC, de Koning HJ, Xu DM, Hoogsteden HC, van Klaveren RJ. How to deal with incidentally detected pulmonary nodules less than 10mm in size on CT in a healthy person. Lung Cancer 60: 151-9, 2008. Revue narrative.

Vazquez M, Carter D, Brambilla E, Gazdar A, Noguchi M, Travis WD, et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 2009 May;64(2):148-54. Etude rétrospective.

Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P, Paganelli G, et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer 2008 Sep;61(3):340-9.Etude prospective

Veronesi G, Bellomi M, Scanagatta P, Preda L, Rampinelli C, Guarize J, et al. Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. J Thorac Cardiovasc Surg 2008 Sep;136(3):611-7.Etude prospective

Whitlock EP, Lin JS, Chou R, Shekelle P, Robinson KA. Using existing systematic reviews in complex systematic reviews. Ann Intern Med 2008 May 20;148(10):776-82.Article de méthodologie.

Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med. 2008;178:956-961.Etude rétrospective.

Yau G, Lock M, Rodrigues G. Systematic review of baseline low-dose CT lung cancer screening. Lung Cancer 58: 161-70, 2007.Revue systématique.

Yu YY, Pinsky PF, Caporaso NE, et al. Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial. Arch Intern Med. 2008;168:2326-2332.Etude de cohorte.

Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C, Nikonova EV, et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 2009 Dec 15;69(24):9202-10.Etude cas-contrôles

Adams K, Shah PL, Edmonds L, Lim E. Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax 2009 Sep;64(9):757-62. Revue systématique avec méta-analyse de la littérature.

Eberhardt R, Ernst A, Herth FJ. Ultrasound-guided transbronchial biopsy of solitary pulmonary nodules less than 20 mm. Eur Respir J 2009 Dec;34(6):1284-7.Etude prospective.

Ernst A, Anantham D, Eberhardt R, Krasnik M, Herth FJ. Diagnosis of mediastinal adenopathy-real-time endobronchial ultrasound guided needle aspiration versus mediastinoscopy. J Thorac Oncol 3: 577-82, 2008.Etude prospective.

Ernst A, Simoff M, Ost D, Goldman Y, Herth FJ. Prospective risk-adjusted morbidity and mortality outcome analysis after therapeutic bronchoscopic procedures: results of a multi-institutional outcomes database. Chest 2008 Sep;134(3):514-9. Etude prospective.

Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer 2009 May;45(8):1389-96. Revue systématique.

Herth FJ, Morgan RK, Eberhardt R, Ernst A. Endobronchial ultrasound-guided miniforceps biopsy in the biopsy of subcarinal masses in patients with low likelihood of non-small cell lung cancer. Ann Thorac Surg 85: 1874-8, 2008.Etude de faisabilité.

Koegelenberg CF, Bolliger CT, Plekker D, Wright CA, Brundyn K, Louw M, et al. Diagnostic yield and safety of ultrasound-assisted biopsies in superior vena cava syndrome. Eur Respir J 2009 Jun;33(6):1389-95. Etude prospective.

Kuo CH, Lin SM, Chen HC, Chou CL, Yu CT, Kuo HP. Diagnosis of peripheral lung cancer with three echoic features via endobronchial ultrasound. Chest 2007 Sep;132(3):922-9.Etude prospective de cohorte.

Lee P, de BR, Brokx HA, Leemans CR, Postmus PE, Sutedja TG. Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: Is there a role for autofluorescence bronchoscopy? Lung Cancer 2008 Dec;62(3):309-15.Etude prospective.

Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Kubo R, Mohammed S, et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007 Aug;132(2):597-602. Etude prospective.

Ost D, Shah R, Anasco E, Lusardi L, Doyle J, Austin C, et al. A randomized trial of CT fluoroscopic-guided bronchoscopy vs conventional bronchoscopy in patients with suspected lung cancer. Chest 2008 Sep;134(3):507-13. Etude randomisée.

Rintoul RC, Tournoy KG, El DH, Carroll NR, Buttery RC, van KK, et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes-an international multi-centre experience. J Thorac Oncol 2009 Jan;4(1):44-8. Etude prospective (commerciale)

Sawhney MS, Bakman Y, Holmstrom AM, Nelson DB, Lederle FA, Kelly RF. Impact of preoperative endoscopic ultrasound on non-small cell lung cancer staging. Chest 2007 Sep;132(3):916-21Etude rétrospective avec groupe contrôle contemporain.

Thiberville L, Salaun M, Lachkar S, Dominique S, Moreno-Swirc S, Vever-Bizet C, et al. Human in vivo fluorescence microimaging of the alveolar ducts and sacs during bronchoscopy. Eur Respir J 2009 May;33(5):974-85.Etude de faisibilité

Tournoy KG, De RF, Vanwalleghem LR, Vermassen F, Praet M, Aerts JG, Van MG, van Meerbeeck JP. Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial. Am J Respir Crit Care Med 177: 531-5, 2008. Etude randomisée.

Wallace MB, Pascual JM, Raimondo M, Woodward TA, McComb BL, Crook JE, et al. Minimally invasive endoscopic staging of suspected lung cancer. JAMA 2008 Feb 6;299(5):540-6. Etude séquentielle.

Williamson JP, McLaughlin RA, Phillips MJ, Armstrong JJ, Becker S, Walsh JH, et al. Using optical coherence tomography to improve diagnostic and therapeutic bronchoscopy. Chest 2009 Jul;136(1):272-6. Etude prospective.

Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, et al. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008 Feb;31(2):280-6.Etude cas-contrôle.

Ameille J, Brochard P, Letourneux M, Paris C, Pairon JC. Risque de cancer lié à l'amiante en présence d'asbestose ou de plaques pleurales. Rev Mal Respir 2009 Apr;26(4):413-21. Revue narrative.

Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 357: 2277-84, 2007.Revue narrative.

Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007 Jul;132(1):185-92.Etude rétrospective de cohorte

Cassidy A, Balsan J, Vesin A, Wu X, Liloglou T, Brambilla C, et al. Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe. Eur J Cancer 2009 Nov;45(17):3047-53. Etude cas-contrôle.

Cassidy A, Myles JP, van TM, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008 Jan 29;98(2):270-6.Etude cas-contrôle.

Chen F, Bina WF, Cole P. Declining incidence rate of lung adenocarcinoma in the United States. Chest 131: 1000-5, 2007. Etude de registre

Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009 Oct 10;374(9697):1243-51. Analyse rétrolective d'une étude randomisée.

de Torres JP, Bastarrika G, Wisnivesky JP, Alcaide AB, Campo A, Seijo LM, et al. Assessing the Relationship Between Lung Cancer Risk and Emphysema Detected on Low-Dose CT of the Chest. Chest 2007 Dec;132(6):1932-8.Etude de cohorte.

Driver JA, Djousse L, Logroscino G et al. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ 2008;337:a2467.Etude de cohorte.

Gray A, Read S, McGale P, Darby S. Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. BMJ 2009;338:a3110.Etude coût-efficacité.

Henderson DW, Rodelsperger K, Woitowitz HJ, Leigh J. After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997-2004. Pathology 36: 517-50, 2004.Revue narrative.

Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008 Nov 13;359(20):2143-53Revue narrative.

Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131: 1282-8, 2007.Etude cas-témoins.

Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007 Dec 10;25(35):5570-7.Etude de registre.

Raine R, Wong W, Scholes S, Ashton C, Obichere A, Ambler G. Social variations in access to hospital care for patients with colorectal, breast, and lung cancer between 1999 and 2006: retrospective analysis of hospital episode statistics. BMJ 2010;340:b5479.Etude de registre.

Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007 Dec 20;25(36):5785-92.Etude cas-contrôle.

Slatore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010 Mar 20;28(9):1540-6. Etude de cohorte

Tang N, Wu Y, Zhou B, Wang B, Yu R. Green tea, black tea consumption and risk of lung cancer: a meta-analysis. Lung Cancer 2009 Sep;65(3):274-83.

Méta-analyse.

Tredaniel J, arab-Terrisse S, Teixeira L, Savinelli F, Fraboulet S, Gossot D, et al. Pollution atmosphérique et cancer bronchique : données épidémiologiques. Rev Mal Respir 2009 Apr;26(4):437-45.Revue narrative.

Tanai C, Nokihara H, Yamamoto S, Kunitoh H, Yamamoto N, Sekine I, et al. Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials. Br J Cancer 2009 Apr 7;100(7):1037-42.Etude rétrospective.

Benlloch S, Galbis-Caravajal JM, Alenda C et al. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases. Ann Oncol 2009 January;20(1):91-7.Etude prospective

Berghmans T, Mascaux C, Haller A, Meert AP, Van HP, Sculier JP. EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer 2008 Oct;62(1):35-44.Etude rétrospective.

Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009 Apr 1;27(10):1667-74.Etude rétrospective.

Carrillo de Santa PE, Arias FC, Caso PE, Munoz Molina GM, Sanchez H, I, Muguruza T, I, et al. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009 Apr 15;115(8):1701-12.Etude rétrospective.

Cooper WA, Kohonen-Corish MR, Zhuang L, McCaughan B, Kennedy C, Screaton G, Sutherland RL, Lee CS. Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 113: 135-42, 2008.Etude rétrospective.

Fan J, Wang L, Jiang GN, He WX, Ding JA. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 61: 91-6, 2008.Méta-analyse de la littérature.

Galleges Ruiz MI, Floor K, Steinberg SM et al. Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer 2009 January 13;100(1):145-52. Etude rétrospective.

Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008 Feb 20;26(6):856-62. Etude rétrospective.

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010 Apr 1;28(10):1721-6.

Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, Yokomise H. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 44: 1057-67, 2008. Etude rétrospective.

Miyoshi K, Moriyama S, Kunitomo T, Nawa S. Prognostic impact of intratumoral vessel invasion in completely resected pathologic stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2009 Feb;137(2):429-34.Etude rétrospective.

Mohamed S, Yasufuku K, Nakajima T et al. Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications. Eur Respir J 2009 January;33(1):127-33.Etude rétrospective.

Nose N, Sugio K, Oyama T et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009 January 20;27(3):411-7. Etude rétrospective.

Renouf DJ, Wood-Baker R, Ionescu DN, Leung S, Masoudi H, Gilks CB, et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009 Apr;4(4):486-91.Etude rétrospective.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009 Sep 3;361(10):958-67. Etude prospective.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 Sep 10;27(26):4247-53. Etude rétrospective.

Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 2009 Mar;137(3):615-21. Etude rétrospective.

Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009 Sep;4(9):1094-103. méta-analyse.

Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 112: 2765-73, 2008. Etude rétrospective.

Anami Y, Iijima T, Suzuki K, Yokota J, Minami Y, Kobayashi H, et al. Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis. J Thorac Oncol 2009 Aug;4(8):951-8. Etude rétrospective.

Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008 Jan 1;26(1):54-9.Etude rétrospective.

Chang JW, Asamura H, Kawachi R, Watanabe S. Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? J Thorac Cardiovasc Surg 2009 Apr;137(4):807-12.Etude rétrospective.

Dujon C, Azarian R, Petitpretz P. Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV. Caractéristiques et facteurs pronostiques à partir d'une série rétrospective . Rev Mal Respir 2009 Nov;26(9):952-60. Etude rétrospective.

Jacot W, Colinet B, Bertrand D, Lacombe S, Bozonnat MC, Daures JP, et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 2008 Aug;19(8):1458-64.Etude de validation.

Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM, Jr., Deming RL, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 2009 Jun 15;115(12):2721-31. Etude rétrospective.

Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010 May;5(5):620-30. Etude rétrospective.

Margolis KL, Rodabough RJ, Thomson CA, Lopez AM, McTiernan A. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med 2007 Sep 24;167(17):1837-44.Etude de cohorte.

Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R. Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol 2009 Dec;4(12):1524-9. Etude de registre.

Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, Suki D, et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer 2009 Jul 1;115(13):2930-8. Etude rétrospective.

Ou SH, Zell JA, Ziogas A, nton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 2007 Oct 1;110(7):1532-41.Etude de registre

Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 2009 January;4(1):37-43.Etude rétrospective.

Puri V, Garg N, Engelhardt EE, Kreisel D, Crabtree TD, Meyers BF, et al. Tumor location is not an independent prognostic factor in early stage non-small cell lung cancer. Ann Thorac Surg 2010 Apr;89(4):1053-9. Etude rétrospective.

Qi Y, Schild SE, Mandrekar SJ, Tan AD, Krook JE, Rowland KM, et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol 2009 Sep;4(9):1075-82. Etude rétrospective.

Sakuma Y, Okamoto N, Saito H, Yamada K, Yokose T, Kiyoshima M, et al. A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size. Lung Cancer 2009 Jul;65(1):85-90.Etude rétrospective.

Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009 Jul;45(11):1950-8. Etude rétrospective.

Wheatley-Price P, Ma C, Ashcroft LF, Nankivell M, Stephens RJ, White SC, et al. The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. Ann Oncol 2010 Feb;21(2):232-7. Analyse de banque d'essais cliniques.

Wheatley-Price P, Le MA, Ding K, Leighl N, Hirsh V, Seymour L, et al. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thorac Oncol 2010 May;5(5):640-8. Analyse de banque d'essais cliniques.

Baty F, Facompre M, Kaiser S, Schumacher M, Pless M, Bubendorf L, et al. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. Am J Respir Crit Care Med 2010 Jan 15;181(2):181-8. Etude prospective.

Huang YT, Heist RS, Chirieac LR, Lin X, Skaug V, Zienolddiny S, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. J Clin Oncol 2009 Jun 1;27(16):2660-7. Etude rétrospective.

In KH, Kwon YS, Oh IJ, Kim KS, Jung MH, Lee KH, et al. Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study. Lung Cancer 2009 May;64(2):232-7. Etude de registre.

Inamura K, Shimoji T, Ninomiya H, Hiramatsu M, Okui M, Satoh Y, Okumura S, Nakagawa K, Noda T, Fukayama M, Ishikawa Y. A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity. Hum Pathol 38: 702-9, 2007.

Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007 Dec 10;25(35):5562-9.Etude rétrospective.

Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, Oka T, Gong Y, Guo R, Inada H, Nawa K, Kojika M, Suga Y, Ohira T, Mukai K, Kato H. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer 98: 596-603, 2008.Etude prospective.

Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007 Apr 23;96(8):1155-8.Revue narrative.

Reed CE, Graham A, Hoda RS, Khoor A, Garrett-Mayer E, Wallace MB, Mitas M. A simple two-gene prognostic model for adenocarcinoma of the lung. J Thorac Cardiovasc Surg 135: 627-34, 2008. Etude rétrospective.

Moriya Y, Iyoda A, Kasai Y, Sugimoto T, Hashida J, Nimura Y, et al. Prediction of lymph node metastasis by gene expression profiling in patients with primary resected lung cancer. Lung Cancer 2009 Apr;64(1):86-91.Etude rétrospective.

Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J, Shibata T, Sugimura H, Gemma A, Kudoh S, Wang XW, Harris CC. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 99: 1257-69, 2007.Etude cas-témoin.

Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010 Apr 7;102(7):464-74. Revue systématique.

Singhal S, Miller D, Ramalingam S, Sun SY. Gene expression profiling of Non-small cell lung cancer. Lung Cancer 60: 313-24, 2008.Revue narrative.

Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008 Feb 20;26(6):877-83.Etude de banques de données.

Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009 Jun 10;27(17):2793-9. Etude rétrospective.

Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112: 1325-36, 2008.Etude rétrospective.

Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007.Etude cas-témoin

Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 99: 858-67, 2007.

Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol 2007 Oct;2(10):893-901.Etude cas-témoins

Zhu ZH, Sun BY, Ma Y et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer. J Clin Oncol 2009 March 1;27(7):1091-9.Etude prospective.

Ou SH, Zell JA. Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies. J Thorac Oncol 2009 Aug 20;4:1202-11. Etude de registre

Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009 Apr 20;27(12):2030-7.Test diagnostique.

Detterbeck FC, Gibson CJ. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 3: 781-92, 2008.Revue systématique.

Hillerdal G. Indolent lung cancers - time for a paradigm shift: a review. J Thorac Oncol 2008 Mar;3(3):208-11.Revue narrative.

Raz DJ, Zell JA, Ou SH, Gandara DR, nton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 2007 Jul;132(1):193-9.Etude de registre

Mortensen EM, Copeland LA, Pugh MJ, Fine MJ, Nakashima B, Restrepo MI, et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia. Am J Med 2010 Jan;123(1):66-71. Etude rétrospective.

Shahid M, Malik A, Bhargava R. Bronchogenic carcinoma and secondary aspergillosis--common yet unexplored: evaluation of the role of bronchoalveolar lavage-polymerase chain reaction and some nonvalidated serologic methods to establish early diagnosis. Cancer 2008 Aug 1;113(3):547-58.Etude de cohorte.

Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008 Sep 20;26(27):4410-7.Etude rétrospective.

Finn OJ. Cancer immunology. N Engl J Med 358: 2704-15, 2008. Revue narrative.

Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009 Jan;33(1):118-26.Etude rétrospective.

Green MR, Dowlati A, Yellamraju L, Daniels L, Willey J, Andrews M, et al. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006. J Thorac Oncol 2007 Oct;2(10):953-6.Enquête.

Stevens W, Stevens G, Kolbe J, et al. Management of stages I and II non-small-cell lung cancer in a New Zealand study: divergence from international practice and recommendations. Intern Med J. 2008Audit

Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007 Sep 20;25(27):4278-84.Etude de phase II randomisée.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009 Jun 1;27(16):2653-9.Etude prospective.

Cappuzzo F, Janne PA, Skokan M et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009 February;20(2):298-304.Etude rétrospective.

Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007 Oct;58(1):95-103.Revue méthodologique de littérature.

Crino L, Cappuzzo F, Zatloukal P, Reck M, Pesek M, Thompson JC, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008 Sep 10;26(26):4253-60.Etude de phase II randomisée (commerciale)

D'Addario G, Rauch D, Stupp R, Pless M, Stahel R, Mach N, Jost L, Widmer L, Tapia C, Bihl M, Mayer M, Ribi K, Lerch S, Bubendorf L, Betticher DC. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 19: 739-45, 2008.Etude de phase II.

Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol 2009 Jun;4(6):684-8. Etude rétrospective.

Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25: 4743-50, 2007.etude de phase II randomisée.

Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007 Sep 20;25(27):4270-7.Etude de phase II randomisée.

Heymach JV, Paz-Ares L, De BF, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5407-5415.Etude de phase II randomisée (commerciale).

Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA, Jr., Franklin WA. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 112: 1114-21, 2008.Etude rétrospective.

Hotta K, Kiura K, Takigawa N, Yoshioka H, Harita S, Kuyama S, et al. Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol 2010 Feb;5(2):179-84. Etude rétrospective.

Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009 March 20;27(9):1394-400. Etude de phase II (académique)

Kaira K, Naito T, Takahashi T, Ayabe E, Shimoyama R, Kaira R, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 2010 Apr;68(1):99-104. Analyse poolée.

Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26: 2450-6, 2008.Etude phase III (commerciale)

Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809-1818.Etude phase III (commerciale)

Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008 Feb 20;26(6):863-9.Etude de phase II randomisée.

Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-77, 2008. Etude prospective.

Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008 Sep 10;26(26):4244-52.Etude randomisée (commerciale).

Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26: 1472-8, 2008.Etude rétrospective.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3;361(10):947-57. EZtude de phase III randomisée (commerciale).

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442-9, 2008.Etude de phase II (commerciale).

Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008 Dec 1;26(34):5589-95.Etude rétrospective (académique)

Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T, Fukuoka M. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98: 907-14, 2008.Etude de phase II (académique).

Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J, et al. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol 2010 Feb;21(2):217-22. Etude de phase II (commerciale)

Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Jr., Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19: 1053-9, 2008.Etude rétrospective.

Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008 Sep;19(9):1605-12.Etude prospective.

Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Cheng AL, Pao W, Yang PC. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26: 2745-53, 2008.Etude de phase II.

Zhu CQ, da Cunha SG, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 Sep 10;26(26):4268-75.Etude rétrospective (commerciale).

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 Jun 24;362(25):2380-8.Etude de phase III (académique)

Grosshans DR, Meyers CA, Allen PK, Davenport SD, Komaki R. Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation. Cancer 2008 Feb 1;112(3):589-95.Etude prospective.

Manapov F, Klautke G, Fietkau R. Prevalence of brain metastases immediately before prophylactic cranial irradiation in limited disease small cell lung cancer patients with complete remission to chemoradiotherapy: a single institution experience. J Thorac Oncol 3: 652-5, 2008.Etude rétrospective.

Pottgen C, Eberhardt W, Grannass A, Korfee S, Stuben G, Teschler H, Stamatis G, Wagner H, Passlick B, Petersen V, Budach V, Wilhelm H, Wanke I, Hirche H, Wilke HJ, Stuschke M. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 25: 4987-92, 2007. Etude de phase III randomisée (schéma complexe à multiples objectifs).

Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009 Jan 1;27(1):78-84.Etude de phase III randomisée (académique)

Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008 Mar 13;358(11):1118-28.Etude cas-contrôle.

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008 Aug 26.Etude prospective

Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008 Jan;59(1):95-104.Etude rétrospective.

Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007 Jul;132(1):200-6.Série prospective.

Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007 Dec 20;25(36):5770-6.Analyse rétrolective.

Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008 Feb;19(2):370-3.Etude de phase II.

Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26: 1698-704, 2008.Etude de phase III.

Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371: 1685-94, 2008. Etude randomisée (académique).

Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009 Apr 20;27(12):2081-90.Revue narrative.

Patients' preferences within randomised trials: systematic review and patient level meta-analysis. BMJ. 2008;337:a1864.Revue systématique.

Berner ES, Graber ML. Overconfidence as a cause of diagnostic error in medicine. Am J Med 121: S2-23, 2008; Revue.

Booth CM, Le MA, Ding K, Farn K, Fralick M, Phillips C, et al. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol 2009 Aug 20;27(24):3938-44. Etude de littérature.

Chan JK, Ueda SM, Sugiyama VE, Stave CD, Shin JY, Monk BJ, Sikic BI, Osann K, Kapp DS. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol 26: 1511-8, 2008.Analyse de la littérature.

Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. BMJ 2009;338:b1732.Revue.

Freidlin B, Korn EL, George SL, Gray R. Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol 25: 5019-23, 2007.Réflexion.

Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews? BMJ 336: 1472-4, 2008.Réflexion.

Grunkemeier GL, Wu Y, Furnary AP. What is the value of a p value? Ann Thorac Surg 2009 May;87(5):1337-43.

Guédon JC. Repenser le sens de la communication scientifique : l'accès libre. Med Sci (Paris) 24: 641-6, 2008. Article général

Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. Br J Haematol 2009 Jun;146(1):27-30. Revue.

Lenzer J. Truly independent research? BMJ 2008;337:602-6. Article général.

Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 2007 Oct 3;99(19):1455-61.Etude

Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009 Aug 20;27(24):4027-34.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. Article méthodologique.

Pentheroudakis G, Stahel R, Hansen H, et al. Heterogeneity in cancer guidelines: should we eradicate or tolerate? Ann Oncol. 2008;19:2067-2078. Analyse de la littérature.

Murray DM, Pals SL, Blitstein JL, Alfano CM, Lehman J. Design and analysis of group-randomized trials in cancer: a review of current practices. J Natl Cancer Inst 100: 483-91, 2008.Revue de la littérature.

Shuchman M. Commercializing clinical trials : risks and benefits of the CRO boom. N Engl J Med 357: 1365-8, 2007.Commentaire.

Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009 February;122(2):114-20. Article général.

Sniderman AD, Furberg CD. Why guideline-making requires reform. JAMA 2009 Jan 28;301(4):429-31.Commentaire.

Tricco AC, Tetzlaff J, Pham B, Brehaut J, Moher D. Non-Cochrane vs. Cochrane reviews were twice as likely to have positive conclusion statements: cross-sectional study. J Clin Epidemiol 2009 Apr;62(4):380-6.Etude de littérature.

Trotta F, Apolone G, Garattini S, Tafuri G. Stopping a trial early in oncology: for patients or for industry? Ann Oncol 19: 1347-53, 2008.Analyse de la littérature.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med 357: 2189-94, 2007.Revue narrative.

Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336: 601-5, 2008.Méta-analyse de la littérature.

Yank V, Rennie D, Bero LA. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 2007 Dec 8;335(7631):1202-5.Etude rétrospective.

Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA 297: 2112-20, 2007.

Burt JR, Iribarren C, Fair JM, Norton LC, Mahbouba M, Rubin GD, et al. Incidental findings on cardiac multidetector row computed tomography among healthy older adults: prevalence and clinical correlates. Arch Intern Med 2008 Apr 14;168(7):756-61.Etude rétrospective.

van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009 Dec 3;361(23):2221-9.Etude prospective.

Erridge SC, Murray B, Williams L, Brewster D, Black R, Price A, et al. Improved survival from lung cancer in British Columbia compared to Scotland-are different treatment rates the whole story? Lung Cancer 2009 Jun;64(3):358-66.

Etude de registre.

Gould MK, Ghaus SJ, Olsson JK, Schultz EM. Timeliness of care in veterans with non-small cell lung cancer. Chest 133: 1167-73, 2008.Etude rétrospective.

Olsson JK, Schultz EM, Gould MK. Timeliness of care in patients with lung cancer: a systematic review. Thorax 2009 Sep;64(9):749-56. Revue systématique.

Saint-Jacques N, Rayson D, Al-Fayea T, Virik K, Morzycki W, Younis T. Waiting times in early-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2008 Aug;3(8):865-70.Etude rétrospective.

Vinod SK, O'Connell DL, Simonella L, Delaney GP, Boyer M, Peters M, et al. Gaps in optimal care for lung cancer. J Thorac Oncol 2008 Aug;3(8):871-9.Etude rétrospective.

Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009 Jul 20;27(21):3540-6.Etude rétrospective.

Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008 Dec 2;99(11):1757-62.Revue narrative.

Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cancer Chemother Pharmacol 2009 Aug;64(3):565-73. Etude rétrospective.

Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007 Oct;2(10):902-6.Etude rétrospective.

Ceppi P, Longo M, Volante M, Novello S, Cappia S, Bacillo E, Selvaggi G, Saviozzi S, Calogero R, Papotti M, Scagliotti GV. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 3: 583-9, 2008. Etude rétrospective.

Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008 Feb 20;26(6):848-55.Exploitation rétrospective dans le contexte d'une étude randomisée.

Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3:1468-1481. Revue narrative.

Holm B, Mellemgaard A, Skov T, Skov BG. Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non-Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine. J Clin Oncol 2009 Aug 10. Etude rétrospective.

Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zochbauer-Muller S, Kuhrer I, Mittlbock M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Muller MR, Roth E, Klepetko W. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J Thorac Cardiovasc Surg 135: 1036-41, 2008. Etude de phase II (académique).

Kim HT, Lee JE, Shin ES, Yoo YK, Cho JH, Yun MH, et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 2008 Dec 20;26(36):5972-9.Etude rétrospective (académique)

Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Jr., et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008 Oct 10;26(29):4771-6. Etude rétrospective

Mohamed S, Yasufuku K, Nakajima T, Hiroshima K, Kubo R, Iyoda A, et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response. Thorax 2008 Jul;63(7):642-7.Etude prospective.

Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008 Oct;62(1):105-12.Etude rétrospective

Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009 Apr;64(1):98-104.Etude rétrospective.

Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008;75(4):380-5. Etude prospective.

Tsao MS, viel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007 Nov 20;25(33):5240-7.Exploitation rétrospective dans le contexte d'une étude randomisée.

Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer 113: 150-7, 2008.Méta-analyse de la littérature.

Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 2010 Mar;46(4):735-43. Analyse rétrolective d'études prospectives.

Erridge SC, Murray B, Price A, Ironside J, Little F, Mackean M, Walker W, Brewster DH, Black R, Fergusson RJ. Improved treatment and survival for lung cancer patients in South-East Scotland. J Thorac Oncol 3: 491-8, 2008.Etude de registre.

Grivaux M, Zureik M, Marsal L, Asselain B, Peureux M, Chavaillon JM, et al. Survie à cinq ans des cancers bronchiques primitifs dans les centres hospitaliers généraux. Rev Mal Respir 2009 Jan;26(1):37-44.Etude de registre

Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer 2010 Jan;67(1):120-3. Etude rétrospective.

Registres d'essais cliniques : vers un meilleur accès aux données sur les traitements. Rev Prescrire 28: 536-41, 2008.Excellente mise au point.

Curfman GD, Morrissey S, Annas GJ, Drazen JM. Peer review in the balance. N Engl J Med 358: 2276-7, 2008. Editorial.

Flanagin A, Carey LA, Fontanarosa PB, Phillips SG, Pace BP, Lundberg GD, Rennie D. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280: 222-4, 1998.Enquête.

Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagin A, Yank V, MacLennan G, Gotzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA 287: 2769-71, 2002.Enquête.

Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 299: 1800-12, 2008. Etude de cas d'études.

Sculier JP. Les publications médicales : vrais ou faux auteurs. Rev Med Brux 2009 Mar;30(2):115-7.Article d'opinion.

Mills ME, Murray LJ, Johnston BT et al. Does a patient-held quality-of-life diary benefit patients with inoperable lung cancer? J Clin Oncol 2009 January 1;27(1):70-7. Etude randomisée.

Pat K, Dooms C, Vansteenkiste J. Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: how CONSORTed are the data? Lung Cancer 2008 Oct;62(1):126-38.Revue systématique.

Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol 2007 Dec;2(12):1091-7.Revue systématique.

Arrieta O, Gallardo-Rincon D, Villarreal-Garza C, Michel RM, storga-Ramos AM, Martinez-Barrera L, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 2009 Jul;4(7):845-52. Etude de phase II (académique)

Berghmans T, Van HP, Paesmans M, Giner V, Lecomte J, Koumakis G, et al. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. Lung Cancer 2009 May;64(2):187-93. Etude randomisée (académique).

De Ruysscher D, Botterweck A, Dirx M et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009 January;20(1):98-102.Etude d'implémentation.

Gayed IW, Chang J, Kim EE, Nunez R, Chasen B, Liu HH, et al. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol 2008 Aug;3(8):858-64.Etude prospective.

Gayed IW, Liu HH, Wei X et al. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 2009 February;4(2):179-84. Etude cas-témoin

Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008 Dec 10;26(35):5755-60. Etude randomisée de phase III (commerciale)

Socinski MA, Blackstock AW, Bogart JA, Wang X, Munley M, Rosenman J, Gu L, Masters GA, Ungaro P, Sleeper A, Green M, Miller AA, Vokes EE. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26: 2457-63, 2008.Etude randomisée de phase II (académique)

Bogart JA, Watson D, McClay EF, Evans L, Herndon JE, Laurie F, et al. Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer 2008 Oct;62(1):92-8.Analyse rétrolective.

Sculier JP, Lafitte JJ, Efremidis A, Florin MC, Lecomte J, Berchier MC, et al. A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. Ann Oncol 2008 Oct;19(10):1691-7.Etude de phase III randomisée (académique).

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009 Jul 10;27(20):3290-6. Etude prospective.

Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, et al. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008 Aug 20;26(24):4001-11. Revue systématique.

Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010 Feb 20;28(6):928-35. Etude rétrospective.

Haasbeek CJ, Lagerwaard FJ, de JK et al. Outcomes of stereotactic radiotherapy for a new clinical stage I lung cancer arising postpneumonectomy. Cancer 2009 February 1;115(3):587-94. Etude rétrospective.

Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer 2010 Jan 15;116(2):406-14. Etude rétrospective.

Pennathur A, Luketich JD, Heron DE, Abbas G, Burton S, Chen M, et al. Stereotactic radiosurgery for the treatment of stage I non-small cell lung cancer in high-risk patients. J Thorac Cardiovasc Surg 2009 Mar;137(3):597-604. Etude rétrospective.

Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 2007 Dec 10;25(35):5557-61.Etude rétrospective.

Rusthoven KE, Hammerman SF, Kavanagh BD et al. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 2009; 48(4):578-83. Etude rétrospective.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010 Mar 17;303(11):1070-6. Etude prospective.

van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans AM, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010 Mar 10;28(8):1380-6. Etude prospective.

Wisnivesky JP, Halm E, Bonomi M, Powell C, Bagiella E. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med 2010 Feb 1;181(3):264-9. Etude de registre.

Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGF{beta}1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009 Jul 10;27(20):3370-8. Etude rétrospective.

de Cabanyes CS, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010 Mar;5(3):389-98. Revue systématique.

Herth FJ, Annema JT, Eberhardt R, Yasufuku K, Ernst A, Krasnik M, et al. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. J Clin Oncol 2008 Jul 10;26(20):3346-50.Etude rétrospective.

Traitement du cancer bronchique à petites cellules : peu d'effet sur la survie et très coûteux. Prescrire 2009;29(307):378-9.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008 Sep 25;359(13):1367-80.Revue narrative.

Meert AP, Sculier JP. What has the meta-analysis contributed to today's standard of care in the treatment of thoracic malignancies? Lung Cancer 2008 August;61(2):141-51.Revue narrative.

Blumenschein GR, Jr., Khuri FR, von PJ, Gatzemeier U, Miller WH, Jr., Jotte RM, Le TJ, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 26: 1879-85, 2008.Etude de phase III.

Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008 Mar;19(3):420-32. Recommandations d'experts.

Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 99: 14-22, 2008. Méta-analyse.

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009 May 2;373(9674):1532-42.Méta-analyse.I

Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncol 26: 2342-9, 2008.Etude randomisée (commerciale).

Lorenz KA, Lynn J, Dy SM, Shugarman LR, Wilkinson A, Mularski RA, et al. Evidence for improving palliative care at the end of life: a systematic review. Ann Intern Med 2008 Jan 15;148(2):147-59. Revue systématique

Qaseem A, Snow V, Shekelle P, Casey DE, Jr., Cross JT, Jr., Owens DK, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008 Jan 15;148(2):141-6. Recommandations.

Temel JS, McCannon J, Greer JA, Jackson VA, Ostler P, Pirl WF, et al. Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. Cancer 2008 Aug 15;113(4):826-33.Etude prospective.

Chansky K, Sculier JP, Crowley JJ, Giroux D, Van MJ, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009 Jul;4(7):792-801. Etude rétrospective.

Dediu M, Crisan E, Radut M et al. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study. Lung Cancer 2009 February;63(2):271-6. Etude de cohorte.

Detterbeck FC, Tanoue LT, Boffa DJ. Anatomy, biology and concepts, pertaining to lung cancer stage classification. J Thorac Oncol 2009 Apr;4(4):437-43.Commentaire

Demir A, Turna A, Kocaturk C, Gunluoglu MZ, Aydogmus U, Urer N, et al. Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer. Ann Thorac Surg 2009 Apr;87(4):1014-22.Etude rétrospective.

Fukui T, Mori S, Hatooka S, Shinoda M, Mitsudomi T. Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. J Thorac Cardiovasc Surg 2008 Nov;136(5):1343-8.Etude rétrospective.

Giroux DJ, Rami-Porta R, Chansky K, Crowley JJ, Groome PA, Postmus PE, et al. The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol 2009 Jun;4(6):679-83. Article d'opinion.

Hsu PK, Huang HC, Hsieh CC, Hsu HS, Wu YC, Huang MH, et al. Effect of formalin fixation on tumor size determination in stage I non-small cell lung cancer. Ann Thorac Surg 2007 Dec;84(6):1825-9.Etude rétrospective.

Goldstraw P, Crowley J, on behalf of the IASLC International Staging Project. The International Association for the Study of Lung Cancer international staging project on lung cancer. J Thorac Oncol 2006;1(4):281-6.

Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007 Aug;2(8):706-14.Etude rétrospective.

Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007 Aug;2(8):694-705.Etude rétrospective.

Kameyama K, Takahashi M, Ohata K, Igai H, Yamashina A, Matsuoka T, et al. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution. J Thorac Cardiovasc Surg 2009 May;137(5):1180-4. Etude rétrospective.

Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. Ann Thorac Surg 2008 Oct;86(4):1092-7.Etude rétrospective.

Kassis ES, Vaporciyan AA, Swisher SG, Correa AM, Bekele BN, Erasmus JJ, et al. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg 2009 Aug;138(2):412-8. Etude rétrospective.

Lee JG, Lee CY, Bae MK, et al. Validity of International Association for the Study Of Lung Cancer proposals for the revision of N descriptors in lung cancer. J Thorac Oncol. 2008;3:1421-1426.Etude rétrospective.

Li Z, Yu Y, Lu J, Luo Q, Wu C, Liao M, et al. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J Thorac Oncol 2009 Jun;4(6):702-9. Etude rétrospective.

Mizuno T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mochizuki T, et al. Identification of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer 2008 Dec;62(3):302-8.Etude rétrospective.

Na II, Cheon GJ, Choe dH, Byun BH, Kang HJ, Koh JS, Park JH, Baek H, Ryoo BY, Lee JC, Yang SH. Clinical significance of (18)F-FDG uptake by N2 lymph nodes in patients with resected stage IIIA N2 non-small-cell lung cancer: A retrospective study. Lung Cancer 60: 69-74, 2008.Etude rétrospective.

Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol 2008 Mar;3(3):216-27.Etude de registre.

Ou SH, Zell JA, Ziogas A, nton-Culver H. Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. Chest 133: 662-9, 2008.Etude de registre.

Ou SH, Ziogas A, Zell JA. Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 2009 Jan;4(1):37-43.Etude rétrospective.

Postmus PE, Brambilla E, Chansky K, Crowley J, Goldstraw P, Patz EF, Jr., et al. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2007 Aug;2(8):686-93.Etude rétrospective.

Rami-Porta R, Ball D, Crowley J, Giroux DJ, Jett J, Travis WD, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007 Jul;2(7):593-602.Etude rétrospective.

Rao J, Sayeed RA, Tomaszek S, Fischer S, Keshavjee S, Darling GE. Prognostic factors in resected satellite-nodule T4 non-small cell lung cancer. Ann Thorac Surg 84: 934-8, 2007. Etude rétrospective.

Rusch VW, Crowley J, Giroux DJ, Goldstraw P, Im JG, Tsuboi M, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007 Jul;2(7):603-12.Etude rétrospective.

Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009 May;4(5):568-77.Article théorique.

Sakakura N, Mori S, Ishiguro F, Fukui T, Hatooka S, Shinoda M, et al. Subcategorization of resectable non-small cell lung cancer involving neighboring structures. Ann Thorac Surg 2008 Oct;86(4):1076-83.Etude rétrospective.

Sakakura N, Mori S, Okuda K, Fukui T, Hatooka S, Shinoda M, et al. Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion. Ann Thorac Surg 2008 Oct;86(4):1084-90.Etude rétrospective.

Sculier JP, Chansky K, Crowley JJ, Van MJ, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 3: 457-66, 2008. Etude rétrospective.

Shepherd FA, Crowley J, Van HP, Postmus PE, Carney D, Chansky K, et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007 Dec;2(12):1067-77.Etude rétrospective.

Shim HS, Park IK, Lee CY, Chung KY. Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer. Lung Cancer 2009 Aug;65(2):161-5. Etude rétrospective.

Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, et al. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008 Nov;3(11):1213-23.Etude rétrospective.

Travis WD, Brambilla E, Rami-Porta R, et al. Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3:1384-1390.Revue de littérature.

Tsuchiya T, Hashizume S, Akamine S, Muraoka M, Honda S, Tsuji K, Urabe S, Hayashi T, Yamasaki N, Nagayasu T. Upstaging by vessel invasion improves the pathology staging system of non-small cell lung cancer. Chest 132: 170-7, 2007.Etude rétrospective.

Vallieres E, Shepherd FA, Crowley J, Van HP, Postmus PE, Carney D, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009 Sep;4(9):1049-59. Etude rétrospective.

William WN, Jr., Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009 Sep;136(3):701-9. Etude de registre.

Yoshida J, Nagai K, Asamura H, Goya T, Koshiishi Y, Sohara Y, et al. Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database. J Thorac Oncol 2009 Aug;4(8):959-63. Etude rétrospective.

Ye C, Masterman JR, Huberman MS, Gangadharan SP, McDonald DC, Kent MS, et al. Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience. Chest 2009 Sep;136(3):710-5.Etude rétrospective.

Zell JA, Ignatius Ou SH, Ziogas A, nton-Culver H. Validation of the proposed International Association for the Study of Lung Cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry. J Thorac Oncol 2007 Dec;2(12):1078-85. Etude rétrospective.

Sugiyama T, Hirose T, Hosaka T, Kusumoto S, Nakashima M, Yamaoka T, et al. Effectiveness of intensive follow-up after response in patients with small cell lung cancer. Lung Cancer 2008 Feb;59(2):255-61.Etude rétrospective.

van Loon J., Grutters J, Wanders R, Boersma L, Oellers M, Dingemans AM, et al. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study. Eur J Cancer 2009 Mar;45(4):588-95. Etude prospective.

Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010 May 1;28(13):2191-7. Etude de registre.

Wang T, Nelson RA, Bogardus A, Grannis FW, Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 2010 Mar 15;116(6):1518-25.Etude rétrospective

Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008 Sep 10;26(26):4276-81.Etude de cohorte.

Cooley ME, Sarna L, Kotlerman J, Lukanich JM, Jaklitsch M, Green SB, et al. Smoking cessation is challenging even for patients recovering from lung cancer surgery with curative intent. Lung Cancer 2009 Nov;66(2):218-25. Etude rétrospective.

Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008 Dec 3;100(23):1672-94.Etude de registre.

Lee YJ, Cho BC, Jee SH, Moon JW, Kim SK, Chang J, et al. Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 2010 Jan 20;28(3):487-92. Etude de cohorte.

Lightwood JM, Glantz SA. Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation 2009 Oct 6;120(14):1373-9. Méta-analyse.

Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569. Revue systématique.

Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, et al. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol 2009 Jul;20(7):1257-63. Etude rétrospective.

Cerfolio RJ, Bryant AS. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy? Ann Thorac Surg 2007 Oct;84(4):1092-7.Etude rétrospective.

Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN, Jr. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med 2008 Jul 28;168(14):1541-9.Etude rétrospective.

Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008 Oct;62(1):55-61.Etude exploratoire.

de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer 2007 Oct 15;110(8):1654-64.Revue systématique.

De WW, Stroobants S, Coolen J, Verschakelen JA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 2009 Jan;33(1):201-12.Revue narrative.

Dooms C, van BA, Verbeken E, van Suylen RJ, Stroobants S, De RD, et al. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol 2009 Jul;4(7):822-8. Etude rétrospective.

Dooms C, Verbeken E, Stroobants S, Nackaerts K, De LP, Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008 Mar 1;26(7):1128-34.Etude rétrospective.

Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009 Jul 2;361(1):32-9 Etude randomisée.

Goudarzi B, Jacene HA, Wahl RL. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med 2008 Oct;49(10):1585-92.Etude rétrospective.

Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF, Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 26: 1459-64, 2008.Etude rétrospective.

Kased N, Erasmus JJ, Komaki R, Cox JD. Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review. J Thorac Oncol 3: 534-8, 2008.Revue narrative.

Kozower BD, Meyers BF, Reed CE, Jones DR, Decker PA, Putnam JB, Jr. Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thorac Surg 85: 1166-9, 2008.analyse rétrolective.

Lee DH, Kim SK, Lee HY, Lee SY, Park SH, Kim HY, et al. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol 2009 Jul;4(7):816-21. Etude prospective.

Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009 Aug 18;151(4):221-48. Etude randomisée.

Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 2009 Dec;4(12):1473-9. Méta-analyse.

Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010 May;5(5):612-9. Méta-analyse de la littérature.

Subedi N, Scarsbrook A, Darby M, Korde K, Mc SP, Muers MF. The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer. Lung Cancer 2009 Jun;64(3):301-7. Etude rétrospective.

Tournoy KG, Maddens S, Gosselin R, Van MG, van Meerbeeck JP, Kelles A. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax 2007 Aug;62(8):696-701.Etude prospective.

Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, Evans WK. 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review. J Natl Cancer Inst 2007.Revue systématique

van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Hing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, De RD. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1 alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43: 1392-8, 2007.

Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, et al. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007 Dec 20;25(36):5777-84.Etude randomisée.

Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008 Jul 10;26(20):3351-7. Etude prospective.

Kelly K, Huang C. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol 3: 664-73, 2008.Revue narrative.

Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099. J Clin Oncol 2010 Feb 20;28(6):911-7.Etude randomisée (commerciale)

Pirker R, Pereira JR, Szczesna A, von PJ, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009 May 2;373(9674):1525-31.Etude de phase III randomisée (commerciale)

Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009 Jul;4(7):911-9. Revue systématique.

Traitement des métastases cérébrales

Lee DH, Han JY, Kim HT, Yoon SJ, Pyo HR, Cho KH, Shin SH, Yoo H, Lee SH, Lee JS. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study. Cancer 113: 143-9, 2008.Etude randomisée (académique)

Yang SY, Kim DG, Lee SH, Chung HT, Paek SH, Hyun KJ, Jung HW, Han DH. Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer 112: 1780-6, 2008.Etude cas-témoins rétrospective.

Endo C, Miyamoto A, Sakurada A, Aikawa H, Sagawa M, Sato M, et al. Results of long-term follow-up of photodynamic therapy for roentgenographically occult bronchogenic squamous cell carcinoma. Chest 2009 Aug;136(2):369-75. Etude rétrospective.

Patel A, Anraku M, Darling GE, Shepherd FA, Pierre AF, Waddell TK, et al. Venous thromboembolism in patients receiving multimodality therapy for thoracic malignancies. J Thorac Cardiovasc Surg 2009 Oct;138(4):843-8.Etude rétrospective.

van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, Tjan-Heijnen VC, Biesma B, Debruyne C, Van ZN, Splinter TA, Giaccone G. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99: 442-50, 2007.Etude de phase III.

Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, et al. DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J Clin Oncol 2008 Jul 20;26(21):3560-6.Etude cas-témoins

Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer 113: 5-21, 2008.Revue narrative.

Incarbone M, Ceresoli GL, Di TL, Cappuzzo F, Inzirillo F, Infante M, et al. Primary pulmonary meningioma Report of a case and review of the literature. Lung Cancer 2008 Dec;62(3):401-7.Cas clinique.

Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 2008 Oct;44(15):2178-84.etude de pase III (académique)

Neninger VE, de la TA, Osorio RM, Catala FM, Bravo I, Mendoza del PM, Abreu AD, Acosta BS, Rives R, del Castillo CC, Gonzalez DM, Viada C, Garcia VB, Crombet RT, Gonzalez MG, Lage DA. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26: 1452-8, 2008.Etude de phase II randomisée (académique).